We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JKHY:NASDAQJack Henry & Associates, Inc. Analysis

Data as of 2026-05-23 - not real-time

$140.19

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Jack Henry & Associates (JKHY) is trading at $140.19, well below its 20‑day, 50‑day and 200‑day moving averages, signaling a short‑term bearish technical backdrop. The RSI sits near 38, hinting at modest oversold conditions, while a bearish MACD reinforces downside pressure. Despite the technical weakness, the company posted a 10.6% YoY revenue increase to $636.2 M in Q1 FY2026 and beat GAAP EPS expectations by 14.9%, underscoring resilient operating performance.
Fundamentally, JKHY delivers strong profitability with a 20.6% net margin, 24.4% operating margin and a 24.9% ROE, and its PE ratio of ~19 is well below the industry average of ~39, suggesting relative value. The dividend yield of 1.7% is backed by a 32.8% payout ratio and robust free cash flow, supporting sustainability. Analyst consensus remains bullish with a “Buy” rating from 14 analysts and price targets near $190‑$193, indicating upside potential despite a DCF‑derived fair value of $97. The stock’s low beta (~0.14) and moderate volatility (~30% 30‑day) point to limited market‑wide risk, though sector and regulatory considerations merit attention.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Current price below key moving averages
  • Recent earnings beat and dividend stability
  • Support level near $132 offering downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Consistent revenue growth and strong margins
  • Analyst price targets indicating ~35% upside
  • Low beta and solid cash flow supporting earnings continuity

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Recurring revenue from core banking platforms
  • High ROE and sustainable dividend yield
  • Strategic share repurchase program enhancing shareholder value

Key Metrics & Analysis

Financial Health

Revenue Growth8.70%
Profit Margin20.64%
P/E Ratio19.6
ROE24.89%
ROA13.66%
Debt/Equity6.40
P/B Ratio4.7
Op. Cash Flow$786.4M
Free Cash Flow$373.4M
Industry P/E39.5

Technical Analysis

TrendBearish
RSI38.5
Support$132.36
Resistance$156.09
MA 20$145.09
MA 50$152.48
MA 200$163.36
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair Value$97.24
Target Price$189.21
Upside/Downside34.97%
GradeFair
TypeBlend
Dividend Yield1.70%

Risk Assessment

Beta0.14
Volatility29.38%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.